Table 4 Treatment outcomes of the Radiation Therapy Oncology Group 8502 regimen for head and neck cancer
Author | Year | Design | N | Population | SCC(%) | Age (years) | Systemic therapy (%) | RT technique | Treatment cycle (%) | Outcome | Toxicity (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2D-RT | 3D-CRT | IMRT | 1 | 2 | 3 | 4 | 5 | TR (%) | SR (%) | OR (%) | OS (months) | PFS (months) | G2 | G3 | ||||||||
Paris [4] | 1993 | Phase I–II | 37 | Incurable H&N tumors | 79 | 66 | 0 | 100 | 0 | 0 | 43c | 57 | 0 | 0 | 77 | 85 | NA | 4.5 | NA | NA | NA | |
Corrya [5] | 2005 | Phase II | 30 | Incurable HNSCC | 100 | 73 | 0 | 100 | 0 | 0 | 20 | 27 | 53 | 0 | 0 | 53 | 56 | NA | 5.7 | 3.1 | 37d | 0 |
Chen [6] | 2008 | R | 23b | Metastatic HNSCC | 100 | 70 | 0 | 20 | 65 | 15 | 26c | 74 | 0 | 0 | NA | NA | 83 | 4 | NA | NA | 9 | |
Lok [2] | 2015 | R | 75 | Incurable H&N tumors | 55 | 76 | 29 | 0 | 45 | 55 | 36 | 27 | 32 | 4 | 1 | NA | NA | 65 | 5.7 | NA | 28 | 5 |
Finnegan [7] | 2016 | R | 70 | Stage III–IV HNSCC | 100 | 66 | 56 | 0 | 49 | 51 | 24c | 76 | 0 | 0 | NA | 61 | NA | 3.9 | 3.4 | 20e | 6 | |
Gamez [8] | 2017 | R | 21 | Stage III–IV H&N tumors | NA | 62 | 100 | 0 | 29 | 71 | 0 | 24 | 76 | 0 | 0 | 86 | 100 | NA | 7 | 4 | 35 | 0 |
Our study | R | 34 | Incurable H&N tumors | 82 | 81 | 0 | 0 | 0 | 100 | 18 | 15 | 68 | 0 | 0 | 85 | 77 | 94 | 5.7 | 4.4 | 12 | 0 | |